The Hospital Clínic of Barcelona has established itself as a leading international center for hepatology, particularly in the field of hepatocellular carcinoma. From the pioneering work of hepatologist Joan Rodés at the end of the last century and the beginning of the present one, to the current contributions of Josep Maria Llovet, the institution has consistently advanced the field through a rigorous scientific approach and strong commitment to multicenter, global collaboration. Their current vision, firmly grounded in evidence-based research, has led to the development of a practical yet powerful patient stratification system—the Barcelona Clinic Liver Cancer (BCLC) classification—which provides a flexible framework for guiding patients toward optimal therapeutic strategies. Emerging treatments, including systemic therapies of intraarterial chemotherapy and general chemotherapy, tested in randomized clinical trials for advanced stages of hepatocellular carcinoma, are progressively improving upon traditional management approaches. The path toward better outcomes remains open and continues to evolve. Barcelona is not only a remarkable city but also a global reference point for excellence in hepatology.